Patents by Inventor Xun Zhao

Xun Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117007
    Abstract: The present invention relates to a proliferation enhancer. The enhancer comprises a protein molecule capable of initiating the cellular STATS and/or STAT3 signaling pathway and comprising the intracellular domain, the transmembrane domain and the extracellular domain. The present invention further relates to a lymphocyte expressing the proliferation enhancer and the use thereof as an immunotherapy drug.
    Type: Application
    Filed: February 10, 2022
    Publication date: April 11, 2024
    Inventors: Zhuo HUANG, Yanni Lin, Xun ZHAO, Xiaocui ZHENG
  • Publication number: 20240067673
    Abstract: A modified nucleoside or nucleotide, the 3?-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method based on the nucleoside or nucleotide.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 29, 2024
    Inventors: Xun XU, Bo TENG, Wenwei ZHANG, Ao CHEN, Handong LI, Shengyi YAN, Shitian ZHUO, Liang SHEN, Yonghui ZHANG, Nanfeng GAO, Jie ZHAO, Sha LIAO
  • Patent number: 11839607
    Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 12, 2023
    Assignee: HEFEI KEDA BIO-TECHNOLOGY CO. LTD
    Inventors: Ke Wang, Qianliu Cheng, Zonggui Wang, Yan Geng, Xun Zhao
  • Publication number: 20230040256
    Abstract: An image coloring method includes: acquiring first color a priori information about an image-to-be-colored; transforming the first color a priori information to obtain second color a priori information aligned with the image-to-be-colored; downsampling the image-to-be-colored to obtain a first image feature; performing modulation coloring processing on the first image feature based on the second color a priori information to obtain a second image feature; and upsampling the second image feature based on the second color a priori information to obtain a first colored image, where the first colored image is aligned with the image-to-be-colored.
    Type: Application
    Filed: October 21, 2022
    Publication date: February 9, 2023
    Inventors: Yanze WU, Yu LI, Xintao WANG, Honglun ZHANG, Xun ZHAO, Ying SHAN
  • Publication number: 20210038590
    Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.
    Type: Application
    Filed: February 22, 2019
    Publication date: February 11, 2021
    Applicant: HEFEI KEDA BIO-TECHNOLOGY CO. LTD
    Inventors: Ke WANG, Qianliu CHENG, Zonggui WANG, Yan GENG, Xun ZHAO
  • Publication number: 20190032359
    Abstract: Provided is a solar umbrella. The solar umbrella includes: solar cells packaged on umbrella cloth; umbrella ribs configured for supporting the umbrella cloth; a line concentration device mounted on the umbrella ribs. The line concentration device has sockets. The solar cells are connected to the sockets of the line concentration device.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Bo JIANG, Yanpeng JU, Xun ZHAO
  • Patent number: 8833149
    Abstract: A piston fuel injector detecting device, comprising a base (1), a perspective platform (2), an observation cover (3), a sliding groove (4), an adjusting handle (5), a conducting wire column (6), a supporting plate (7), a tact switch (8), a limit plate (9), an infrared-ray emitting tube (10), an illuminating device (11) and a positioning pin (12), wherein the base (1) is connected with the perspective platform (2) and the positioning pin (12); the perspective platform (2) is connected with the observation cover (3) which is provided with the sliding groove (4); the adjusting handle (5) is connected with the observation cover (3); the conducting wire column (6) is vertically connected with the base (1) and is connected with the supporting plate (7) which is provided with the tact switch (8); the conducting wire column (6) is connected with the limit plate (9) which is connected with the infrared-ray emitting tube (10) and the illuminating device (11).
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: September 16, 2014
    Assignee: Dalian Dexin M & E Technology Engineering Co., Ltd.
    Inventors: Xun Zhao, Yuejin Huang
  • Publication number: 20110158932
    Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.
    Type: Application
    Filed: December 8, 2008
    Publication date: June 30, 2011
    Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
  • Publication number: 20080081781
    Abstract: Methods and compositions containing a berberine compound or berberine related or proto-berberine or derivative compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol.
    Type: Application
    Filed: April 6, 2007
    Publication date: April 3, 2008
    Inventors: Arnold Lippa, Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
  • Publication number: 20060223838
    Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.
    Type: Application
    Filed: September 16, 2005
    Publication date: October 5, 2006
    Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
  • Publication number: 20030064061
    Abstract: Recombinant Bcr-Abl polypeptides that form a stable &agr;-helical structure; nucleic acids encoding recombinant Bcr-Abl polypeptides; methods of identifying or designing inhibitors of Bcr-Abl oligomerization and methods of inhibiting Bcr-Abl oligomerization in cells and in individuals in need of inhibiting Bcr-Abl oligomerization, such as individuals who have developed or are at risk of developing chronic myelogenous leukemia or acute lymphoblastic leukemia.
    Type: Application
    Filed: July 9, 2002
    Publication date: April 3, 2003
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Xun Zhao, Saghi Ghaffari, Harvey F. Lodish, Vladimir N. Malashkevich, Peter S. Kim
  • Publication number: 20010043931
    Abstract: A method of identifying a drug that inhibits the RSV membrane fusion machinery, such as the HRSV membrane fusion machinery; drugs that bind the N-helix coiled-coil of HRSV, particularly the N-helix coiled-coil pocket, and, thus, inhibit HRSV infection of cells, such as human cells; methods of inhibiting (partially or totally) HRSV infection of an individual; anitbodies that bind to the N-helix coiled-coil region of HRSV F1; and pharmaceutical compositions comprising HRSV infection neutralizing antibodies.
    Type: Application
    Filed: December 5, 2000
    Publication date: November 22, 2001
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Xun Zhao, Mona Singh, Vladimir Malashkevich, Peter S. Kim
  • Patent number: PP31244
    Abstract: A new and distinct cultivar of Nelumbo plant named ‘Zhijiang Qiuyue’, characterized by its upright plant habit; moderately vigorous growth habit; large medium green-colored leaves; freely flowering habit; and large pale yellow and green white-colored plated globose-shaped flowers that are positioned above the foliar plane on moderately strong and erect peduncles.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 17, 2019
    Assignee: Zhejiang Renwen Landscape Architecture Co., Ltd.
    Inventors: Xun Zhao, Yuchu Chen
  • Patent number: PP31245
    Abstract: A new and distinct cultivar of Nelumbo plant named ‘Buzeng Jielu’, characterized by its upright plant habit; moderately vigorous growth habit; large medium green-colored leaves; freely flowering habit; and large red purple-colored calathiform flowers that are positioned above the foliar plane on moderately strong and erect peduncles.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 17, 2019
    Assignee: Zhejang Renwen Landscape Architecture Co., Ltd.
    Inventors: Yuchu Chen, Xun Zhao